Zhejiang Jolly Pharmaceutical Co.,LTD

Shenzhen Stock Exchange 300181.SZ

Zhejiang Jolly Pharmaceutical Co.,LTD Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -22.44 M

Zhejiang Jolly Pharmaceutical Co.,LTD Net Cash Used Provided By Financing Activities is USD -22.44 M for the year ending December 31, 2023, a -124.08% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Zhejiang Jolly Pharmaceutical Co.,LTD Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 93.19 M, a 343.73% change year over year.
  • Zhejiang Jolly Pharmaceutical Co.,LTD Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -38.24 M, a -370.23% change year over year.
  • Zhejiang Jolly Pharmaceutical Co.,LTD Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -8.13 M, a 75.00% change year over year.
  • Zhejiang Jolly Pharmaceutical Co.,LTD Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD -32.53 M, a -785.84% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300181.SZ

Zhejiang Jolly Pharmaceutical Co.,LTD

CEO Mr. Tao Wang
IPO Date Feb. 22, 2011
Location China
Headquarters No. 388, Zhiyuan North Road
Employees 2,687
Sector Healthcare
Industries
Description

Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporium, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.

StockViz Staff

February 2, 2025

Any question? Send us an email